ArticleMicrosystems & nanoengineering2026
Iridium complex-loaded biomimetic vesicles enable enhanced photodynamic therapy and immune modulation.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The strategic integration of micro/nano-engineering with controlled optical responses is pivotal for advancing solid tumor therapy. We have constructed a biomimetic nanosystem via the precise encapsulation of a flexible-chain iridium complex (IrC8) within giant plasma membrane vesicles (GPMVs) derived from tumor cells. This micro/nano-scale design leverages the endogenous structure of GPMVs to achieve superior biocompatibility and enhance homologous targeting, resulting in a 4.7% increase in cellular uptake compared to the free complex. The encapsulated IrC8 complex serves as a highly efficient photosensitizer, exhibiting a strong optical response characterized by an aggregation-induced emission enhancement factor (I/I₀) > 10 and a high singlet-oxygen quantum yield (ΦΔ = 0.18). Upon photoactivation, this system generates reactive oxygen species (ROS) with an 18-fold increase in yield, leading to potent phototoxicity with over 90% tumor cell apoptosis. Furthermore, the systematic integration of the vesicular carrier and the photosensitizer initiates a cascade reaction: the photodynamic effect not only directly eradicates tumor cells but also triggers immunogenic cell death (ICD), leading to potent immune activation. This synergistic combination of targeted delivery, photodynamic therapy, and immune stimulation within a single nanosystem demonstrates a remarkable synergistic therapeutic effect against solid tumors.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.